Analysis of CYP2C19 Gene Genotype in Patients with Acute Cerebral Infarction and Its Relationship with Disease Progression

The study aimed to analyze the polymorphism distribution of CYP2C19 gene in patients with acute cerebral infarction, and to explore its relationship with disease progression. Methods: 300 patients were divided into mild stroke group and moderate to severe stroke group. All patients were followed up for seven days to record the advance condition. CYP2C19 gene polymorphisms were detected, including extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM). The distribution of CYP2C19 genotype in patients with acute cerebral infarction was EM (138 cases), IM (137 cases) and PM (25 cases), with allele frequencies of 46.00, 45.67 and 8.33%, respectively. The proportion of EM type in mild group was lower than that in moderate-severe stroke group, while the proportion of IM type and PM type was higher (P < 0.01). In comparison with non-advanced group, patients who advanced to neurological deficit had lower proportion of EM type, higher proportion of IM type and PM type (P < 0.01). IM (HR = 2.199, 95% CI = 1.215–3.979, P = 0.09) and PM (HR = 6.821, 95% CI = 2.230–20.859, P = 0.01) types were independent predictors for the poor neurological function. EM and IM genotypes were the main genotypes of CYP2C19 in patients with acute cerebral infarction in northern Anhui of China. The disease is more severe in patients with IM and PM, who are more likely to develop into neurological deficit.